| Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease D Alsoud, B Van Calster Inflammatory Bowel Diseases 30 (6), 1050-1051, 2024 | | 2024 |
| Reply to: Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease D Famutimi, QA Alayo, P Deepak Inflammatory Bowel Diseases 30 (6), 1052-1052, 2024 | | 2024 |
| Ustekinumab and Vedolizumab Exposure Is Unaffected by Pharmacogenetic Determinants of Anti-TNFs Pharmacokinetics D Alsoud, B Verstockt, S Vermeire Inflammatory Bowel Diseases 30 (5), 874-875, 2024 | | 2024 |
| Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis D Alsoud, J Ho, J Sabino, M Ferrante, S Vermeire, B Verstockt Official journal of the American College of Gastroenterology| ACG 119 (3 …, 2024 | | 2024 |
| Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study D Alsoud, J Sabino, D Franchimont, A Cremer, J Busschaert, F D’Heygere, ... Inflammatory Bowel Diseases, izad315, 2024 | 5 | 2024 |
| The serum-based endoscopic healing index can monitor therapeutic response in Crohn’s disease D Alsoud, J Ho, B Verstockt Journal of Crohn's and Colitis 17 (10), 1703-1704, 2023 | 1 | 2023 |
| Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn … N Van den Berghe, D Alsoud, B Verstockt, S Vermeire, P Declerck, ... Therapeutic Advances in Gastroenterology 16, 17562848231189110, 2023 | | 2023 |
| Comparative Effectiveness Research to Position Therapies in Ulcerative Colitis: How Fair Are the Comparisons? D Alsoud, B Verstockt, S Vermeire Clinical Gastroenterology and Hepatology 21 (5), 1372-1373, 2023 | | 2023 |
| Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis D Alsoud, G De Hertogh, G Compernolle, S Tops, J Sabino, M Ferrante, ... Journal of Crohn's and Colitis 16 (10), 1562–1570, 2022 | 20* | 2022 |
| Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn’s disease: real-life cohort from a tertiary referral center A Moens, D Alsoud, B Verstockt, J Sabino, M Ferrante, S Vermeire European Journal of Gastroenterology & Hepatology 34 (10), 1015-1020, 2022 | 9 | 2022 |
| Tailoring multi-omics to inflammatory bowel diseases: all for one and one for all P Sudhakar, D Alsoud, J Wellens, S Verstockt, K Arnauts, B Verstockt, ... Journal of Crohn's and Colitis 16 (8), 1306-1320, 2022 | 18 | 2022 |
| Translating results from VARSITY to real world: adalimumab vs vedolizumab as first-line biological in moderate to severe IBD A Moens, B Verstockt, D Alsoud, J Sabino, M Ferrante, S Vermeire Inflammatory Bowel Diseases 28 (8), 1135-1142, 2022 | 10 | 2022 |
| Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis B Verstockt, V Volk, C Jaeckel, D Alsoud, J Sabino, S Nikolaus, A Outtier, ... Alimentary Pharmacology & Therapeutics 56 (2), 282-291, 2022 | 8 | 2022 |
| USTEKINUMAB EXPOSURE AFFECTS REAL-WORLD ENDOSCOPIC AND HISTOLOGIC OUTCOMES IN ULCERATIVE COLITIS D Alsoud, G Compernolle, S Tops, J Sabino, M Ferrante, D Thomas, ... Gastroenterology 162 (7), S819-S819, 2022 | | 2022 |
| Mo1558: REAL-WORLD EFFECTIVENESS AND SAFETY OF RISANKIZUMAB FOR MODERATE-SEVERE MULTI-REFRACTORY CROHN’S DISEASE: RESULTS FROM A BELGIAN MULTI-CENTRIC COHORT D Alsoud, D Franchimont, F D’Heygere, P Bossuyt, A Vijverman, ... Gastroenterology 162 (7), S-818-S-819, 2022 | | 2022 |
| Mo1560: USTEKINUMAB EFFECTIVENESS, DRUG PERSISTENCE AND SERUM EXPOSURE IN CROHN’S DISEASE ARE AFFECTED BY ITS POSITIONING D Alsoud, J Sabino, M Ferrante, S Vermeire, B Verstockt Gastroenterology 162 (7), S-819-S-820, 2022 | | 2022 |
| Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology D Alsoud, DJAR Moes, Z Wang, R Soenen, Z Layegh, M Barclay, ... Therapeutic Drug Monitoring, 10.1097, 2022 | | 2022 |
| immunogenicity is not the root cause for loss of response to anti‐TNF agents in patients with IBD in TDM era. D Alsoud, B Verstockt, S Vermeire Alimentary Pharmacology & Therapeutics 55 (7), 2022 | 5 | 2022 |
| Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises D Alsoud, S Vermeire, B Verstockt Current Research in Pharmacology and Drug Discovery 3, 100089, 2022 | 12 | 2022 |
| P447 Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn’s disease D Alsoud, J Sabino, M Ferrante, S Vermeire, B Verstockt Journal of Crohn's and Colitis 16 (Supplement_1), i427-i428, 2022 | 1 | 2022 |
